Clinical trial results to be announced at ASCO 2014 (5/30 to 6/3)

Updated efficacy and safety of the ALK inhibitor AP26113 in patients with advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC). (Abstract 8047)

Antitumor activity of alectinib (CH5424802/RO5424802) for ALK-rearranged NSCLC with or without prior crizotinib treatment in bioequivalence study. (Abstract 8103)

A phase I trial of X-396, a novel ALK inhibitor, in patients with advanced solid tumors. (Abstract 8030^)

Updated phase 1 results for TSR-011 from Tesaro

http://files.shareholder.com/downloads/AMDA-Z6KN1/0x0x749755/ba47b94a-1ce4-45c3-a164-1f42eb303f29/TSROQ1%202014%20slide%20deck%20043014%20FINAL.pdf

Results for RXDX-101 recently licensed from Nerviano in Italy by Ignyta.

http://www.businesswire.com/news/home/20140507006438/en/Ignyta-Announces-RXDX-101-Phase-Data-Abstract-Accepted#.U20Gp5K9KK0

This entry was posted in alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, Lung cancer, Potential Treatments, RXDX-101 - entrectinib - by Ignyta, TSR-011 from Tesaro, X-396 - ensartinib from Xcovrery. Bookmark the permalink.

Leave a Reply